Heamodynamic Effects of Paracetamol in Septic Shock Patients

October 10, 2023 updated by: Ayah Mohammed Khalil

Haemodynamic Effects of Paracetamol (Acetaminophen) as Extended Intravenous Infusion Versus Intravenous Bolus in Septic Shock Patients

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock is defined as sepsis that has circulatory, cellular, and metabolic abnormalities that are associated with a greater risk of mortality than sepsis alone. Clinically, this includes patients who fulfill the criteria for sepsis who, despite adequate fluid resuscitation, require vasopressors to maintain a mean arterial pressure ≥65 mmHg and have a lactate >2 mmol/L (>18 mg/dL). Feve is a common sign of infection in septic shock critically ill patients. Many critically ill patients experience pain. Paracetamol is considered safe and currently one of the most common antipyretics and used as part of multimodal analgesia for acute pain in the intensive care unit. According to the company's product information leaflet, the rate of hypotension complicating intravenous paracetamol treatment ranges from 0.01 to 0.1%. However, recent studies reported a much higher incidence and may be harmful in critically ill adults. The hemodynamic effects of intravenous (IV) paracetamol are unknown in septic shock patients, that the most vulnerable population and hemodynamically unstable.

The aim of this study is to assess the incidence of hypotension of the extended intravenous paracetamol (acetaminophen) infusion over three hours in comparing with intravenous paracetamol bolus over 15 minutes in hemodynamically unstable patients (septic shock).

Study Overview

Status

Completed

Conditions

Detailed Description

Sepsis, inflammatory response to infection, contributes directly or indirectly to mortality in the majority of critically ill patients. An elevated cardiac index and a decreased systemic vascular resistance leading to hypotension and hypoperfusion of vital organs characterize the early stage of septic shock. The hypotensive state is often not amenable to fluid resuscitation alone and requires institution of vasoactive agents to counter the profound fall in systemic vascular resistance, which is an integral feature of septic shock .

Acetaminophen is the antipyretic and analgesic that is most often given to hospitalized patients, including those in critical care units. The mechanism of action of acetaminophen remains incompletely understood, but the antipyretic response appears to be due to blocking cyclooxygenase-II and inhibiting prostaglandin-II synthesis in the central nervous system.

Intravenous (IV) acetaminophen has gained popularity for inpatient management of acute pain for its practical and clinical advantages. IV administration is associated with more predictable pharmacokinetic performance compared with rectal (30%-40% bioavailability) and oral dosage forms of acetaminophen (60%-70% bioavailability).

Predictable kinetics as well as ease of IV administration has made it an especially attractive option in the critically ill patients who have altered gut absorption secondary to numerous pathophysiological and therapeutic influences .

IV acetaminophen has shown promise in improving patient satisfaction, managing fever, and decreasing postoperative opioid requirements. These features have made it one of the most widely ordered medications within critical care and surgical services.

Product information for IV acetaminophen lists mild effects such as nausea or vomiting among the most common adverse events (incidence ≥ 5%), with the estimated incidence of more serious adverse effects such as hypotension being <1%. However, there have been an increasing number of randomized controlled trials which indicated that the incidence of IV acetaminophen-induced hypotension may be higher than previously reported by manufacturers. These publications have prompted investigators to look more closely at the possible untoward effects of IV acetaminophen across a variety of populations. . None of these studies examined whether the extended infusion of IV paracetamol can minimize the degree of hypotension in critically heamodynamic unstable patients.

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt, 11725
        • Cairo University Hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age adult ≥ 18 years old.
  2. The patient fulfills the criteria of septic shock definition:

    • Sepsis needs vasopressor therapy.
    • Serum lactate level greater than 2 mmol/l (SSC 2016).
  3. Patient with contractility greater than 40%

Exclusion Criteria:

  1. paracetamol hypersensitivity or allergy.
  2. Acute liver injury or failure
  3. Childs-Pugh C liver disease
  4. Heat stroke.
  5. Malignant hyperthermia.
  6. Neuroleptic Malignant Syndrome.
  7. Continous renal replacement therapy.
  8. Ventricular assist device.
  9. Around-the-clock scheduled of acetaminophen-containing medications administration or non-steroidal anti-inflammatory drugs.
  10. Pregnancy/lactation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo group
placebo group (100 ml normal saline over 15 minutes)
as placebo
Experimental: bolus group
bolus group (1000mg/100 ml paracetamol over 15 minutes)
compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
Other Names:
  • acetaminophen
Experimental: Extended infusion group
Extended infusion (1000mg/100 ml paracetamol over 3 hours)
compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
Other Names:
  • acetaminophen

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of hypotension .
Time Frame: pre intervention and six hours after the intervantion
defined as a decrease in SBP ≥ 20٪ from baseline, by extended infusion of intravenous paracetamol
pre intervention and six hours after the intervantion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The changes in hemodynamic parameters
Time Frame: pre intervention and six hours after the intervantion
Changes in cardiac output ( L/min)
pre intervention and six hours after the intervantion
The changes in hemodynamic parameters
Time Frame: pre intervention and six hours after the intervantion
Changes in heart rate (bpm)
pre intervention and six hours after the intervantion
The changes in hemodynamic parameters
Time Frame: pre intervention and six hours after the intervantion
Changes in central venous pressure (mmHg)
pre intervention and six hours after the intervantion
The changes in temperature
Time Frame: pre intervention and six hours after the intervantion
Changes in temperature (celsius)
pre intervention and six hours after the intervantion
The changes in vassopresors and fluid bolus
Time Frame: pre intervention and six hours after the intervantion
changes in vassopresors infusion rate (mcg/ min) and fluid bolus
pre intervention and six hours after the intervantion
The changes in hemodynamic parameters
Time Frame: pre intervention and six hours after the intervantion
Changes in mean arterial pressure(mmHg), diastolic blood pressure (mmHg)
pre intervention and six hours after the intervantion
The changes in vassopresors and fluid bolus
Time Frame: pre intervention and six hours after the intervantion
changes in fluid bolus (ml)
pre intervention and six hours after the intervantion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2020

Primary Completion (Actual)

November 1, 2022

Study Completion (Actual)

January 24, 2023

Study Registration Dates

First Submitted

September 25, 2023

First Submitted That Met QC Criteria

October 4, 2023

First Posted (Actual)

October 11, 2023

Study Record Updates

Last Update Posted (Actual)

October 12, 2023

Last Update Submitted That Met QC Criteria

October 10, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Clinical Trials on Normal saline

3
Subscribe